Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy
pOBI was not associated with risk of transaminase elevation in PWH switching to dual therapies lacking anti-HBV agents.
Authors
- Silvia Limonta (ORCID: https://orcid.org/0000-0003-3879-4128)
- Alban Rugova
- Sergio Malandrin
- Anna Cappelletti
- Annalisa Cavallero (ORCID: https://orcid.org/0000-0001-6755-4110)
- Nicola Squillace (ORCID: https://orcid.org/0000-0002-7608-6045)
- Alice Ranzani (ORCID: https://orcid.org/0000-0002-4101-3524)
- Elisa Colella
- Paolo Bonfanti (ORCID: https://orcid.org/0000-0001-7289-8823)
- Giuseppe Lapadula (ORCID: https://orcid.org/0000-0002-9976-8102)
- Ilaria Caramma
- Luca Mezzadri (ORCID: https://orcid.org/0009-0000-5652-3204)
- Bianca Monti
- Francesca Sabbatini
- Ana Soria
Institutions
- Azienda Ospedaliera San Gerardo (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- AIDS
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1097/qad.0000000000004227
- Citations
- 5
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 6.61